Viking Therapeutics (VKTX) Assets Average (2016 - 2025)
Viking Therapeutics (VKTX) has disclosed Assets Average for 11 consecutive years, with $727.6 million as the latest value for Q4 2025.
- Quarterly Assets Average fell 21.18% to $727.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $727.6 million through Dec 2025, down 21.18% year-over-year, with the annual reading at $812.0 million for FY2025, 27.2% up from the prior year.
- Assets Average hit $727.6 million in Q4 2025 for Viking Therapeutics, down from $783.6 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $957.2 million in Q2 2024 to a low of $159.7 million in Q1 2023.
- Historically, Assets Average has averaged $480.9 million across 5 years, with a median of $325.7 million in 2023.
- Biggest five-year swings in Assets Average: fell 24.69% in 2022 and later skyrocketed 318.26% in 2024.
- Year by year, Assets Average stood at $217.6 million in 2021, then decreased by 22.96% to $167.6 million in 2022, then soared by 124.08% to $375.6 million in 2023, then skyrocketed by 145.78% to $923.1 million in 2024, then decreased by 21.18% to $727.6 million in 2025.
- Business Quant data shows Assets Average for VKTX at $727.6 million in Q4 2025, $783.6 million in Q3 2025, and $847.4 million in Q2 2025.